[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 5, 2003

Estrogen Replacement and Risk of Alzheimer Disease—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;289(9):1102-1103. doi:10.1001/jama.289.9.1102-a

In Reply: Dr Fukuda and colleagues question whether the effect of the BP intervention was greater for patients randomized to amlodipine than for patients assigned to ramipril or metoprolol. There was no significant relationship between the effect of the BP intervention and the antihypertensive drug group for the primary outcome of GFR slope or the main secondary clinical composite outcome comprising GFR events, end-stage renal disease, or death (P values for the BP by drug group interaction were .64, .61, and .18 for the chronic slope, total slope, and clinical composite outcomes, respectively). Thus, in accordance with the study design, our primary article addressed the overall BP comparison combining the 3 drug groups. Separate comparisons of the BP goals within the individual drug groups will be provided in subsequent publications.

First Page Preview View Large
First page PDF preview
First page PDF preview
×